Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

<p>Supplementary Tables</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Koichi Tomoshige (15304682) (author)
Бусад зохиолчид:	William D. Stuart (15304685) (author), Iris M. Fink-Baldauf (15304688) (author), Masaoki Ito (15304691) (author), Tomoshi Tsuchiya (15304694) (author), Takeshi Nagayasu (15304697) (author), Tomoki Yamatsuji (15304700) (author), Morihito Okada (15038418) (author), Takuya Fukazawa (15304703) (author), Minzhe Guo (15304706) (author), Yutaka Maeda (15304709) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Promoter/enhancer analysis Lung Cancer Oncogenes & Tumor Suppressors Kras
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
-н: Craig M. Goodwin (14955973)
Хэвлэсэн: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
-н: Nicholas T. Younger (14956251)
Хэвлэсэн: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
-н: Nicholas T. Younger (14956251)
Хэвлэсэн: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
-н: Nicholas T. Younger (14956251)
Хэвлэсэн: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
-н: Nicholas T. Younger (14956251)
Хэвлэсэн: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
-н: Dhruv Chachad (14954640)
Хэвлэсэн: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
-н: Dhruv Chachad (14954640)
Хэвлэсэн: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
-н: Dhruv Chachad (14954640)
Хэвлэсэн: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
-н: Dhruv Chachad (14954640)
Хэвлэсэн: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
-н: Dhruv Chachad (14954640)
Хэвлэсэн: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
-н: Man Xu (14963249)
Хэвлэсэн: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
-н: Man Xu (14963249)
Хэвлэсэн: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
-н: Man Xu (14963249)
Хэвлэсэн: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
-н: Man Xu (14963249)
Хэвлэсэн: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
-н: Man Xu (14963249)
Хэвлэсэн: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
-н: Man Xu (14963249)
Хэвлэсэн: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
-н: Man Xu (14963249)
Хэвлэсэн: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
-н: Man Xu (14963249)
Хэвлэсэн: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
-н: Caleb N. Seavey (15056489)
Хэвлэсэн: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
-н: Caleb N. Seavey (15056489)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_8qnfr0358bjbb3temudf9nl7sv